line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,AARTIPHARM.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.244766,AARTIPHARM.NS
Normalized EBITDA,2025-03-31 00:00:00,4744899000.0,AARTIPHARM.NS
Total Unusual Items,2025-03-31 00:00:00,,AARTIPHARM.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,,AARTIPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,2724048000.0,AARTIPHARM.NS
Reconciled Depreciation,2025-03-31 00:00:00,869040000.0,AARTIPHARM.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,11278775000.0,AARTIPHARM.NS
EBITDA,2025-03-31 00:00:00,4744899000.0,AARTIPHARM.NS
EBIT,2025-03-31 00:00:00,3875859000.0,AARTIPHARM.NS
Net Interest Income,2025-03-31 00:00:00,-268964000.0,AARTIPHARM.NS
Interest Expense,2025-03-31 00:00:00,268964000.0,AARTIPHARM.NS
Interest Income,2025-03-31 00:00:00,,AARTIPHARM.NS
Normalized Income,2025-03-31 00:00:00,2724048000.0,AARTIPHARM.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,2724048000.0,AARTIPHARM.NS
Total Expenses,2025-03-31 00:00:00,17376079000.0,AARTIPHARM.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,AARTIPHARM.NS
Diluted Average Shares,2025-03-31 00:00:00,90680692.0,AARTIPHARM.NS
Basic Average Shares,2025-03-31 00:00:00,90620359.0,AARTIPHARM.NS
Diluted EPS,2025-03-31 00:00:00,30.04,AARTIPHARM.NS
Basic EPS,2025-03-31 00:00:00,30.06,AARTIPHARM.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,2724048000.0,AARTIPHARM.NS
Net Income Common Stockholders,2025-03-31 00:00:00,2724048000.0,AARTIPHARM.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,AARTIPHARM.NS
Net Income,2025-03-31 00:00:00,2724048000.0,AARTIPHARM.NS
Minority Interests,2025-03-31 00:00:00,,AARTIPHARM.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,2724048000.0,AARTIPHARM.NS
Net Income Continuous Operations,2025-03-31 00:00:00,2724048000.0,AARTIPHARM.NS
Tax Provision,2025-03-31 00:00:00,882847000.0,AARTIPHARM.NS
Pretax Income,2025-03-31 00:00:00,3606895000.0,AARTIPHARM.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,101192000.0,AARTIPHARM.NS
Special Income Charges,2025-03-31 00:00:00,,AARTIPHARM.NS
Other Special Charges,2025-03-31 00:00:00,,AARTIPHARM.NS
Write Off,2025-03-31 00:00:00,,AARTIPHARM.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-268964000.0,AARTIPHARM.NS
Total Other Finance Cost,2025-03-31 00:00:00,,AARTIPHARM.NS
Interest Expense Non Operating,2025-03-31 00:00:00,268964000.0,AARTIPHARM.NS
Interest Income Non Operating,2025-03-31 00:00:00,,AARTIPHARM.NS
Operating Income,2025-03-31 00:00:00,3774666000.0,AARTIPHARM.NS
Operating Expense,2025-03-31 00:00:00,6097304000.0,AARTIPHARM.NS
Other Operating Expenses,2025-03-31 00:00:00,3608669000.0,AARTIPHARM.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,869040000.0,AARTIPHARM.NS
Amortization,2025-03-31 00:00:00,,AARTIPHARM.NS
Depreciation Income Statement,2025-03-31 00:00:00,869040000.0,AARTIPHARM.NS
Research And Development,2025-03-31 00:00:00,,AARTIPHARM.NS
Selling General And Administration,2025-03-31 00:00:00,,AARTIPHARM.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,AARTIPHARM.NS
General And Administrative Expense,2025-03-31 00:00:00,,AARTIPHARM.NS
Rent And Landing Fees,2025-03-31 00:00:00,,AARTIPHARM.NS
Gross Profit,2025-03-31 00:00:00,9871970000.0,AARTIPHARM.NS
Cost Of Revenue,2025-03-31 00:00:00,11278775000.0,AARTIPHARM.NS
Total Revenue,2025-03-31 00:00:00,21150745000.0,AARTIPHARM.NS
Operating Revenue,2025-03-31 00:00:00,21150745000.0,AARTIPHARM.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,AARTIPHARM.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.278177,AARTIPHARM.NS
Normalized EBITDA,2024-03-31 00:00:00,3909419000.0,AARTIPHARM.NS
Total Unusual Items,2024-03-31 00:00:00,12230000.0,AARTIPHARM.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,12230000.0,AARTIPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,2169020000.0,AARTIPHARM.NS
Reconciled Depreciation,2024-03-31 00:00:00,732353000.0,AARTIPHARM.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,10207173000.0,AARTIPHARM.NS
EBITDA,2024-03-31 00:00:00,3909419000.0,AARTIPHARM.NS
EBIT,2024-03-31 00:00:00,3177066000.0,AARTIPHARM.NS
Net Interest Income,2024-03-31 00:00:00,-172147000.0,AARTIPHARM.NS
Interest Expense,2024-03-31 00:00:00,172147000.0,AARTIPHARM.NS
Interest Income,2024-03-31 00:00:00,30419000.0,AARTIPHARM.NS
Normalized Income,2024-03-31 00:00:00,2169020000.0,AARTIPHARM.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,2169020000.0,AARTIPHARM.NS
Total Expenses,2024-03-31 00:00:00,15397977000.0,AARTIPHARM.NS
Rent Expense Supplemental,2024-03-31 00:00:00,11593000.0,AARTIPHARM.NS
Diluted Average Shares,2024-03-31 00:00:00,90640201.0,AARTIPHARM.NS
Basic Average Shares,2024-03-31 00:00:00,90640201.0,AARTIPHARM.NS
Diluted EPS,2024-03-31 00:00:00,23.93,AARTIPHARM.NS
Basic EPS,2024-03-31 00:00:00,23.93,AARTIPHARM.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,2169020000.0,AARTIPHARM.NS
Net Income Common Stockholders,2024-03-31 00:00:00,2169020000.0,AARTIPHARM.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,AARTIPHARM.NS
Net Income,2024-03-31 00:00:00,2169020000.0,AARTIPHARM.NS
Minority Interests,2024-03-31 00:00:00,,AARTIPHARM.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,2169020000.0,AARTIPHARM.NS
Net Income Continuous Operations,2024-03-31 00:00:00,2169020000.0,AARTIPHARM.NS
Tax Provision,2024-03-31 00:00:00,835899000.0,AARTIPHARM.NS
Pretax Income,2024-03-31 00:00:00,3004919000.0,AARTIPHARM.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,48950000.0,AARTIPHARM.NS
Special Income Charges,2024-03-31 00:00:00,190000.0,AARTIPHARM.NS
Other Special Charges,2024-03-31 00:00:00,-190000.0,AARTIPHARM.NS
Write Off,2024-03-31 00:00:00,,AARTIPHARM.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-172147000.0,AARTIPHARM.NS
Total Other Finance Cost,2024-03-31 00:00:00,,AARTIPHARM.NS
Interest Expense Non Operating,2024-03-31 00:00:00,172147000.0,AARTIPHARM.NS
Interest Income Non Operating,2024-03-31 00:00:00,30419000.0,AARTIPHARM.NS
Operating Income,2024-03-31 00:00:00,3128116000.0,AARTIPHARM.NS
Operating Expense,2024-03-31 00:00:00,5190804000.0,AARTIPHARM.NS
Other Operating Expenses,2024-03-31 00:00:00,3074377000.0,AARTIPHARM.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,732353000.0,AARTIPHARM.NS
Amortization,2024-03-31 00:00:00,12700000.0,AARTIPHARM.NS
Depreciation Income Statement,2024-03-31 00:00:00,732353000.0,AARTIPHARM.NS
Research And Development,2024-03-31 00:00:00,83701000.0,AARTIPHARM.NS
Selling General And Administration,2024-03-31 00:00:00,803586000.0,AARTIPHARM.NS
Selling And Marketing Expense,2024-03-31 00:00:00,679712000.0,AARTIPHARM.NS
General And Administrative Expense,2024-03-31 00:00:00,123874000.0,AARTIPHARM.NS
Rent And Landing Fees,2024-03-31 00:00:00,11593000.0,AARTIPHARM.NS
Gross Profit,2024-03-31 00:00:00,8318920000.0,AARTIPHARM.NS
Cost Of Revenue,2024-03-31 00:00:00,10207173000.0,AARTIPHARM.NS
Total Revenue,2024-03-31 00:00:00,18526093000.0,AARTIPHARM.NS
Operating Revenue,2024-03-31 00:00:00,18526093000.0,AARTIPHARM.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,210274.380423,AARTIPHARM.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.258005,AARTIPHARM.NS
Normalized EBITDA,2023-03-31 00:00:00,3442877000.0,AARTIPHARM.NS
Total Unusual Items,2023-03-31 00:00:00,815000.0,AARTIPHARM.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,815000.0,AARTIPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,1934934000.0,AARTIPHARM.NS
Reconciled Depreciation,2023-03-31 00:00:00,625427000.0,AARTIPHARM.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,12539679000.0,AARTIPHARM.NS
EBITDA,2023-03-31 00:00:00,3443692000.0,AARTIPHARM.NS
EBIT,2023-03-31 00:00:00,2818265000.0,AARTIPHARM.NS
Net Interest Income,2023-03-31 00:00:00,-201144000.0,AARTIPHARM.NS
Interest Expense,2023-03-31 00:00:00,210517000.0,AARTIPHARM.NS
Interest Income,2023-03-31 00:00:00,9373000.0,AARTIPHARM.NS
Normalized Income,2023-03-31 00:00:00,1934329274.380423,AARTIPHARM.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,1934934000.0,AARTIPHARM.NS
Total Expenses,2023-03-31 00:00:00,16564957000.0,AARTIPHARM.NS
Rent Expense Supplemental,2023-03-31 00:00:00,39964000.0,AARTIPHARM.NS
Diluted Average Shares,2023-03-31 00:00:00,90626008.0,AARTIPHARM.NS
Basic Average Shares,2023-03-31 00:00:00,90626008.0,AARTIPHARM.NS
Diluted EPS,2023-03-31 00:00:00,21.35,AARTIPHARM.NS
Basic EPS,2023-03-31 00:00:00,21.35,AARTIPHARM.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,1934934000.0,AARTIPHARM.NS
Net Income Common Stockholders,2023-03-31 00:00:00,1934934000.0,AARTIPHARM.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,AARTIPHARM.NS
Net Income,2023-03-31 00:00:00,1934934000.0,AARTIPHARM.NS
Minority Interests,2023-03-31 00:00:00,0.0,AARTIPHARM.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,1934935000.0,AARTIPHARM.NS
Net Income Continuous Operations,2023-03-31 00:00:00,1934935000.0,AARTIPHARM.NS
Tax Provision,2023-03-31 00:00:00,672813000.0,AARTIPHARM.NS
Pretax Income,2023-03-31 00:00:00,2607748000.0,AARTIPHARM.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,493000.0,AARTIPHARM.NS
Special Income Charges,2023-03-31 00:00:00,-580000.0,AARTIPHARM.NS
Other Special Charges,2023-03-31 00:00:00,580000.0,AARTIPHARM.NS
Write Off,2023-03-31 00:00:00,59000.0,AARTIPHARM.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-201144000.0,AARTIPHARM.NS
Total Other Finance Cost,2023-03-31 00:00:00,14185000.0,AARTIPHARM.NS
Interest Expense Non Operating,2023-03-31 00:00:00,210517000.0,AARTIPHARM.NS
Interest Income Non Operating,2023-03-31 00:00:00,9373000.0,AARTIPHARM.NS
Operating Income,2023-03-31 00:00:00,2795088000.0,AARTIPHARM.NS
Operating Expense,2023-03-31 00:00:00,4025278000.0,AARTIPHARM.NS
Other Operating Expenses,2023-03-31 00:00:00,813797000.0,AARTIPHARM.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,625427000.0,AARTIPHARM.NS
Amortization,2023-03-31 00:00:00,443000.0,AARTIPHARM.NS
Depreciation Income Statement,2023-03-31 00:00:00,624984000.0,AARTIPHARM.NS
Research And Development,2023-03-31 00:00:00,139605000.0,AARTIPHARM.NS
Selling General And Administration,2023-03-31 00:00:00,881930000.0,AARTIPHARM.NS
Selling And Marketing Expense,2023-03-31 00:00:00,737537000.0,AARTIPHARM.NS
General And Administrative Expense,2023-03-31 00:00:00,144393000.0,AARTIPHARM.NS
Rent And Landing Fees,2023-03-31 00:00:00,39964000.0,AARTIPHARM.NS
Gross Profit,2023-03-31 00:00:00,6820366000.0,AARTIPHARM.NS
Cost Of Revenue,2023-03-31 00:00:00,12539679000.0,AARTIPHARM.NS
Total Revenue,2023-03-31 00:00:00,19360045000.0,AARTIPHARM.NS
Operating Revenue,2023-03-31 00:00:00,19360045000.0,AARTIPHARM.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,29423.552778,AARTIPHARM.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.213214,AARTIPHARM.NS
Normalized EBITDA,2022-03-31 00:00:00,1978253000.0,AARTIPHARM.NS
Total Unusual Items,2022-03-31 00:00:00,138000.0,AARTIPHARM.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,138000.0,AARTIPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,1222511000.0,AARTIPHARM.NS
Reconciled Depreciation,2022-03-31 00:00:00,421186000.0,AARTIPHARM.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,8796993000.0,AARTIPHARM.NS
EBITDA,2022-03-31 00:00:00,1978391000.0,AARTIPHARM.NS
EBIT,2022-03-31 00:00:00,1557205000.0,AARTIPHARM.NS
Net Interest Income,2022-03-31 00:00:00,-119530000.0,AARTIPHARM.NS
Interest Expense,2022-03-31 00:00:00,3401000.0,AARTIPHARM.NS
Interest Income,2022-03-31 00:00:00,57000.0,AARTIPHARM.NS
Normalized Income,2022-03-31 00:00:00,1222402423.552778,AARTIPHARM.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,1222511000.0,AARTIPHARM.NS
Total Expenses,2022-03-31 00:00:00,10268713000.0,AARTIPHARM.NS
Rent Expense Supplemental,2022-03-31 00:00:00,1151000.0,AARTIPHARM.NS
Diluted Average Shares,2022-03-31 00:00:00,90626008.0,AARTIPHARM.NS
Basic Average Shares,2022-03-31 00:00:00,90626008.0,AARTIPHARM.NS
Diluted EPS,2022-03-31 00:00:00,13.489627,AARTIPHARM.NS
Basic EPS,2022-03-31 00:00:00,13.489627,AARTIPHARM.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,1222511000.0,AARTIPHARM.NS
Net Income Common Stockholders,2022-03-31 00:00:00,1222511000.0,AARTIPHARM.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,AARTIPHARM.NS
Net Income,2022-03-31 00:00:00,1222511000.0,AARTIPHARM.NS
Minority Interests,2022-03-31 00:00:00,,AARTIPHARM.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,1222511000.0,AARTIPHARM.NS
Net Income Continuous Operations,2022-03-31 00:00:00,1222511000.0,AARTIPHARM.NS
Tax Provision,2022-03-31 00:00:00,331293000.0,AARTIPHARM.NS
Pretax Income,2022-03-31 00:00:00,1553804000.0,AARTIPHARM.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,-3213000.0,AARTIPHARM.NS
Special Income Charges,2022-03-31 00:00:00,138000.0,AARTIPHARM.NS
Other Special Charges,2022-03-31 00:00:00,-208000.0,AARTIPHARM.NS
Write Off,2022-03-31 00:00:00,70000.0,AARTIPHARM.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-119530000.0,AARTIPHARM.NS
Total Other Finance Cost,2022-03-31 00:00:00,116186000.0,AARTIPHARM.NS
Interest Expense Non Operating,2022-03-31 00:00:00,3401000.0,AARTIPHARM.NS
Interest Income Non Operating,2022-03-31 00:00:00,57000.0,AARTIPHARM.NS
Operating Income,2022-03-31 00:00:00,1651623000.0,AARTIPHARM.NS
Operating Expense,2022-03-31 00:00:00,1471720000.0,AARTIPHARM.NS
Other Operating Expenses,2022-03-31 00:00:00,644350.0,AARTIPHARM.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,421186000.0,AARTIPHARM.NS
Amortization,2022-03-31 00:00:00,,AARTIPHARM.NS
Depreciation Income Statement,2022-03-31 00:00:00,421186000.0,AARTIPHARM.NS
Research And Development,2022-03-31 00:00:00,,AARTIPHARM.NS
Selling General And Administration,2022-03-31 00:00:00,276448000.0,AARTIPHARM.NS
Selling And Marketing Expense,2022-03-31 00:00:00,261364000.0,AARTIPHARM.NS
General And Administrative Expense,2022-03-31 00:00:00,15084000.0,AARTIPHARM.NS
Rent And Landing Fees,2022-03-31 00:00:00,1151000.0,AARTIPHARM.NS
Gross Profit,2022-03-31 00:00:00,3123343000.0,AARTIPHARM.NS
Cost Of Revenue,2022-03-31 00:00:00,8796993000.0,AARTIPHARM.NS
Total Revenue,2022-03-31 00:00:00,11920336000.0,AARTIPHARM.NS
Operating Revenue,2022-03-31 00:00:00,11920336000.0,AARTIPHARM.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,AARTIPHARM.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,AARTIPHARM.NS
Normalized EBITDA,2021-03-31 00:00:00,,AARTIPHARM.NS
Total Unusual Items,2021-03-31 00:00:00,0.0,AARTIPHARM.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,0.0,AARTIPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,AARTIPHARM.NS
Reconciled Depreciation,2021-03-31 00:00:00,,AARTIPHARM.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,AARTIPHARM.NS
EBITDA,2021-03-31 00:00:00,,AARTIPHARM.NS
EBIT,2021-03-31 00:00:00,,AARTIPHARM.NS
Net Interest Income,2021-03-31 00:00:00,,AARTIPHARM.NS
Interest Expense,2021-03-31 00:00:00,,AARTIPHARM.NS
Interest Income,2021-03-31 00:00:00,0.0,AARTIPHARM.NS
Normalized Income,2021-03-31 00:00:00,,AARTIPHARM.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,AARTIPHARM.NS
Total Expenses,2021-03-31 00:00:00,,AARTIPHARM.NS
Rent Expense Supplemental,2021-03-31 00:00:00,0.0,AARTIPHARM.NS
Diluted Average Shares,2021-03-31 00:00:00,,AARTIPHARM.NS
Basic Average Shares,2021-03-31 00:00:00,,AARTIPHARM.NS
Diluted EPS,2021-03-31 00:00:00,,AARTIPHARM.NS
Basic EPS,2021-03-31 00:00:00,,AARTIPHARM.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,AARTIPHARM.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,AARTIPHARM.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,AARTIPHARM.NS
Net Income,2021-03-31 00:00:00,,AARTIPHARM.NS
Minority Interests,2021-03-31 00:00:00,,AARTIPHARM.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,AARTIPHARM.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,AARTIPHARM.NS
Tax Provision,2021-03-31 00:00:00,,AARTIPHARM.NS
Pretax Income,2021-03-31 00:00:00,,AARTIPHARM.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,AARTIPHARM.NS
Special Income Charges,2021-03-31 00:00:00,0.0,AARTIPHARM.NS
Other Special Charges,2021-03-31 00:00:00,,AARTIPHARM.NS
Write Off,2021-03-31 00:00:00,0.0,AARTIPHARM.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,AARTIPHARM.NS
Total Other Finance Cost,2021-03-31 00:00:00,,AARTIPHARM.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,AARTIPHARM.NS
Interest Income Non Operating,2021-03-31 00:00:00,0.0,AARTIPHARM.NS
Operating Income,2021-03-31 00:00:00,,AARTIPHARM.NS
Operating Expense,2021-03-31 00:00:00,,AARTIPHARM.NS
Other Operating Expenses,2021-03-31 00:00:00,,AARTIPHARM.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,AARTIPHARM.NS
Amortization,2021-03-31 00:00:00,,AARTIPHARM.NS
Depreciation Income Statement,2021-03-31 00:00:00,,AARTIPHARM.NS
Research And Development,2021-03-31 00:00:00,,AARTIPHARM.NS
Selling General And Administration,2021-03-31 00:00:00,46000.0,AARTIPHARM.NS
Selling And Marketing Expense,2021-03-31 00:00:00,0.0,AARTIPHARM.NS
General And Administrative Expense,2021-03-31 00:00:00,46000.0,AARTIPHARM.NS
Rent And Landing Fees,2021-03-31 00:00:00,0.0,AARTIPHARM.NS
Gross Profit,2021-03-31 00:00:00,,AARTIPHARM.NS
Cost Of Revenue,2021-03-31 00:00:00,,AARTIPHARM.NS
Total Revenue,2021-03-31 00:00:00,,AARTIPHARM.NS
Operating Revenue,2021-03-31 00:00:00,,AARTIPHARM.NS
